Pharmacogenomic Study for Providing Personalized Strategy to the Treatment of Non-small Cell Lung Cancer (NSCLC) IIIB/IV

NCT01003964 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

289

Enrollment

OTHER_GOV

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: IP
DRUG: GP

Sponsor

National Cancer Center, Korea